PPARG and neurodegenerative disease: Then Abbas et al. [142] found that a PPARγ agonist can both reduce and increase the risk of cardiovascular events, while Chen et al. [143] studied PPARγ receptors in neurodegenerative diseases, finding them to have a significant effect through NF-kappa beta.